We are live on
!
Find out more
E
Ergoteles Portfolio holdings
AUM
$68.2M
1-Year Est. Return
36.16%
This Fund
S&P 500
This Quarter
Est. Return
+13.32%
1 Year Est. Return
+36.16%
3 Year Est. Return
+76.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.72B
AUM Growth
-$123M
(-4.3%)
Cap. Flow
-$215M
Cap. Flow
% of AUM
-7.9%
Top 10 Holdings %
Top 10 Hldgs %
16.65%
Holding
2,200
New
704
Increased
294
Reduced
353
Closed
800
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Biotechnology ETF
IBB
|
+$85.8M |
| 2 |
Steel Dynamics
STLD
|
+$50.2M |
| 3 |
McKesson
MCK
|
+$43.7M |
| 4 |
STOR
STORE Capital Corporation
STOR
|
+$38.2M |
| 5 |
Arch Capital
ACGL
|
+$26M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CTXS
Citrix Systems Inc
CTXS
|
+$149M |
| 2 |
DRE
Duke Realty Corp.
DRE
|
+$147M |
| 3 |
NLSN
Nielsen Holdings plc
NLSN
|
+$44.3M |
| 4 |
CoStar Group
CSGP
|
+$44.2M |
| 5 |
Chevron
CVX
|
+$43.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 15.28% |
| 2 | Healthcare | 12.35% |
| 3 | Industrials | 12.24% |
| 4 | Technology | 10.34% |
| 5 | Consumer Discretionary | 10.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
IMGN
1251
DELISTED
Immunogen Inc
IMGN
| $77.3K | ﹤0.01% |
+15,582
| New | +$84.5K |
|
|
ASXC
1252
DELISTED
Asensus Surgical, Inc.
ASXC
| $76.3K | ﹤0.01% |
219,715
-748,272
| -77% | -$304K |
|
|
SVM
1253
Silvercorp Metals
SVM
$2.05B
| $76.2K | ﹤0.01% |
83,643
-77,308
| -48% | -$209K |
|
1254
Zevra Therapeutics
ZVRA
$562M
| $76.1K | ﹤0.01% |
16,580
-105,420
| -86% | -$535K |
|
1255
Radiant Logistics
RLGT
$408M
| $76.1K | ﹤0.01% |
14,950
-3,250
| -18% | -$18.2K |
|
1256
Personalis
PSNL
$1.24B
| $75.2K | ﹤0.01% |
+37,962
| New | +$95.6K |
|
|
KRON
1257
DELISTED
Kronos Bio
KRON
| $75.2K | ﹤0.01% |
+46,389
| New | +$107K |
|
1258
Alaunos Therapeutics
TCRT
$4.64M
| $74.1K | ﹤0.01% |
761
-2,475
| -76% | -$359K |
|
|
REE
1259
DELISTED
REE Automotive
REE
| $72.6K | ﹤0.01% |
6,228
-6,174
| -50% | -$102K |
|
1260
Getty Images
GETY
$170M
| $71.8K | ﹤0.01% |
12,932
+1,217
| +10% | +$6.81K |
|
1261
Community Health Systems
CYH
$393M
| $71.7K | ﹤0.01% |
16,586
-174,483
| -91% | -$537K |
|
1262
Empire State Realty Trust
ESRT
$976M
| $70.9K | ﹤0.01% |
10,516
-98,918
| -90% | -$697K |
|
|
OKUR
1263
OnKure Therapeutics
OKUR
$154M
| $70.5K | ﹤0.01% |
3,025
-739
| -20% | -$19.6K |
|
|
CLPR
1264
Clipper Realty
CLPR
$46.4M
| $70K | ﹤0.01% |
+10,939
| New | +$76.6K |
|
|
NEXN
1265
Nexxen International
NEXN
$577M
| $67.1K | ﹤0.01% |
+10,400
| New | +$76K |
|
|
LONA
1266
LeonaBio Inc
LONA
$67.4M
| $66.2K | ﹤0.01% |
+2,088
| New | +$65.8K |
|
1267
Santander
BSBR
$41.4B
| $65.8K | ﹤0.01% |
+12,199
| New | +$66.9K |
|
|
SYRS
1268
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $65.3K | ﹤0.01% |
+18,181
| New | +$78.9K |
|
1269
Five Point Holdings
FPH
$396M
| $64.8K | ﹤0.01% |
+27,803
| New | +$62.9K |
|
1270
Applied Digital
APLD
$7.42B
| $64.3K | ﹤0.01% |
+34,950
| New | +$68.9K |
|
|
CARM
1271
DELISTED
Carisma Therapeutics
CARM
| $63.5K | ﹤0.01% |
+5,209
| New | +$54.7K |
|
1272
BGC Group
BGC
$5.68B
| $63.1K | ﹤0.01% |
+16,738
| New | +$66.1K |
|
1273
Cerus
CERS
$583M
| $62.8K | ﹤0.01% |
17,199
-213,079
| -93% | -$803K |
|
1274
Shattuck Labs
STTK
$633M
| $62K | ﹤0.01% |
26,948
-75,777
| -74% | -$190K |
|
|
TGAN
1275
DELISTED
Transphorm, Inc. Common Stock
TGAN
| $61.7K | ﹤0.01% |
+11,349
| New | +$66.8K |
|
Similar funds
ROC
IVMX
AM
JCG
JAMONY
FA
VCM
MCMI
Ergoteles's Q4 2022 Portfolio in Review
As of Q4 2022, Ergoteles held 2,200 positions worth $2.72B, down 4.3% from $2.85B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Ergoteles withdrew a net $215M in Q4 2022, closing 800 positions and reducing 353 holdings. Its most notable exit was Citrix Systems Inc, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Financials at 15% of assets, up from 14% a quarter earlier, followed by Healthcare and Industrials.
Against the trend, Ergoteles opened a new position in McKesson worth $43.9M.
- Ergoteles's largest Q4 2022 buy was McKesson: 117,079 shares worth $43.9M.
- Ergoteles added most to iShares Biotechnology ETF in Q4 2022, an estimated $85.8M increase.
- Ergoteles's biggest Q4 2022 reduction was Alphabet (Google) Class C, cutting an estimated $41.8M.
- Ergoteles fully exited Citrix Systems Inc in Q4 2022, selling an estimated $149M.
- Ergoteles's ten largest holdings make up 17% of its $2.72B portfolio in Q4 2022.
- Ergoteles opened 704 new positions and closed 800 in Q4 2022.
- Ergoteles's portfolio value fell 4.3% quarter-over-quarter to $2.72B.
Based on Ergoteles's 13F filing for Q4 2022, filed 14 Feb 2023.